A detailed history of Two Sigma Investments, LP transactions in I Mab stock. As of the latest transaction made, Two Sigma Investments, LP holds 478,442 shares of IMAB stock, worth $521,501. This represents 0.0% of its overall portfolio holdings.

Number of Shares
478,442
Previous 575,580 16.88%
Holding current value
$521,501
Previous $1.07 Million 25.42%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.58 - $1.9 $153,478 - $184,562
-97,138 Reduced 16.88%
478,442 $798,000
Q1 2024

May 15, 2024

BUY
$1.54 - $2.37 $1,045 - $1,609
679 Added 0.12%
575,580 $1.07 Million
Q4 2023

Feb 14, 2024

BUY
$1.21 - $1.9 $133,311 - $209,332
110,175 Added 23.71%
574,901 $1.09 Million
Q3 2023

Nov 14, 2023

BUY
$1.18 - $3.06 $137,700 - $357,086
116,695 Added 33.53%
464,726 $613,000
Q2 2023

Aug 14, 2023

BUY
$2.95 - $3.85 $322,541 - $420,943
109,336 Added 45.81%
348,031 $1.04 Million
Q1 2023

May 15, 2023

SELL
$3.08 - $7.39 $541,565 - $1.3 Million
-175,833 Reduced 42.42%
238,695 $825,000
Q4 2022

Feb 14, 2023

SELL
$3.22 - $4.86 $190,144 - $286,987
-59,051 Reduced 12.47%
414,528 $1.73 Million
Q3 2022

Nov 14, 2022

BUY
$4.01 - $12.34 $1.71 Million - $5.25 Million
425,279 Added 880.49%
473,579 $1.9 Million
Q2 2022

Aug 15, 2022

SELL
$8.27 - $18.43 $4.03 Million - $8.98 Million
-487,296 Reduced 90.98%
48,300 $546,000
Q1 2022

May 16, 2022

BUY
$12.54 - $46.93 $5.23 Million - $19.6 Million
417,060 Added 351.84%
535,596 $8.7 Million
Q4 2021

Feb 14, 2022

BUY
$45.28 - $74.5 $5.03 Million - $8.28 Million
111,166 Added 1508.36%
118,536 $5.62 Million
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $421,416 - $622,249
7,370 New
7,370 $534,000
Q1 2021

May 17, 2021

SELL
$44.38 - $63.97 $1.05 Million - $1.51 Million
-23,618 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$32.94 - $47.15 $777,976 - $1.11 Million
23,618 New
23,618 $1.11 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $90.6M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.